Qiagen N.V. (NYSE:QGEN) Given Average Rating of “Hold” by Brokerages

Qiagen N.V. (NYSE:QGEN) has been assigned an average rating of “Hold” from the twelve research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $55.1988.

A number of equities analysts recently weighed in on the stock. Barclays set a $58.00 price target on shares of Qiagen and gave the stock an “overweight” rating in a research report on Friday, February 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a report on Friday, March 27th. UBS Group set a $52.00 target price on Qiagen in a report on Monday, February 9th. Stifel Nicolaus set a $50.00 price target on Qiagen and gave the company a “hold” rating in a research report on Friday, February 6th. Finally, Citigroup cut their price target on Qiagen from $55.40 to $55.00 and set a “neutral” rating for the company in a report on Friday, February 6th.

Institutional Trading of Qiagen

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Danske Bank A S acquired a new position in shares of Qiagen during the 3rd quarter valued at about $36,000. Smartleaf Asset Management LLC increased its position in Qiagen by 1,383.3% during the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after purchasing an additional 830 shares during the last quarter. Manchester Capital Management LLC purchased a new position in Qiagen during the fourth quarter worth about $42,000. Global Retirement Partners LLC raised its stake in Qiagen by 279.9% during the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after purchasing an additional 851 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in Qiagen by 375.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock valued at $55,000 after purchasing an additional 980 shares during the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Stock Performance

NYSE QGEN opened at $41.05 on Friday. The firm has a market capitalization of $8.46 billion, a P/E ratio of 20.36, a PEG ratio of 2.12 and a beta of 0.79. The stock has a 50-day simple moving average of $46.37 and a two-hundred day simple moving average of $47.93. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90. Qiagen has a fifty-two week low of $38.79 and a fifty-two week high of $57.81.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.01. The firm had revenue of $540.42 million during the quarter, compared to analyst estimates of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.61 EPS. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, equities analysts forecast that Qiagen will post 2.26 earnings per share for the current year.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.